UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.

3 Micro-Cap Stocks That Could Be Moonshots

10:31pm, Tuesday, 14'th Nov 2023
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and u
UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

Why Shares of uniQure Are Up Thursday

01:49pm, Thursday, 05'th Oct 2023
uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.
Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating e
UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its work

Why Shares of uniQure Are Dropping Tuesday

01:10pm, Tuesday, 05'th Sep 2023
The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.

3 Tantalizing Stocks to Buy for Under $10

03:51pm, Saturday, 26'th Aug 2023
As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the
UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.

Why uniQure Stock Cratered This Week

03:03pm, Thursday, 22'nd Jun 2023
Wednesday, uniQure announced interim phase 1/2 results for its experimental Huntington's disease gene therapy. Results from the high-dose cohort raised more questions than they answered.
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Why uniQure Stock Is Crashing Today

11:46am, Wednesday, 21'st Jun 2023
uniQure reported interim data from a phase 1/2 study of AMT-130 in treating Huntington's disease. The results for the low dose of the gene therapy were promising.
uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such a
UniQure (QURE) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1 per share a year ago.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE